Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) Enterprise Value: 2016-2025

Historic Enterprise Value for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $5.5 billion.

  • Tg Therapeutics' Enterprise Value rose 37.33% to $5.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year increase of 29.95%. This contributed to the annual value of $4.4 billion for FY2024, which is 84.69% up from last year.
  • Latest data reveals that Tg Therapeutics reported Enterprise Value of $5.5 billion as of Q3 2025, which was up 3.46% from $5.3 billion recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Enterprise Value ranged from a high of $6.3 billion in Q1 2021 and a low of $418.1 million during Q2 2022.
  • Its 3-year average for Enterprise Value is $3.5 billion, with a median of $3.6 billion in 2023.
  • Per our database at Business Quant, Tg Therapeutics' Enterprise Value slumped by 91.71% in 2022 and then spiked by 752.84% in 2023.
  • Over the past 5 years, Tg Therapeutics' Enterprise Value (Quarterly) stood at $2.4 billion in 2021, then tumbled by 35.13% to $1.6 billion in 2022, then surged by 52.05% to $2.4 billion in 2023, then spiked by 84.69% to $4.4 billion in 2024, then spiked by 37.33% to $5.5 billion in 2025.
  • Its Enterprise Value was $5.5 billion in Q3 2025, compared to $5.3 billion in Q2 2025 and $5.8 billion in Q1 2025.